Strasbourg, Dijon, France, April 9, 2013 / B3C newswire / - Inventiva and NovAliX announced today that they have entered into a strategic alliance dedicated to the discovery of clinical candidates, targeting nuclear receptors.
After several years of successful collaboration in the field of nuclear receptors and a proven track record with three programs having reached clinical stage, Inventiva and NovAliX are now officially teaming up to establish a solid alliance to further deliver on the therapeutic promises of the nuclear receptor target class.
Through this alliance, Inventiva and NovAliX offer pharmaceutical and biotech companies a unique set of fully integrated nuclear receptor drug discovery capabilities by combining their respective in-depth expertise in structural biology, medicinal chemistry, biology, DMPK, pharmacology and safety. This alliance will leverage Inventiva’s and NovAliX’s diversified proprietary libraries in combination with complementary screening technologies (multiple biophysical techniques combined with biochemical and bio-functional assays). For the first time, pharmaceutical and biotech companies will be able to entrust their entire nuclear receptor drug discovery program from target validation to IND stage to one single experienced partner.
Pierre Broqua, CSO and co-founder of Inventiva, stated “This is a great opportunity for pharmaceutical and biotech companies wishing to engage in discovery collaborations to address this major, therapeutically relevant, target class. Based on our unique drug-discovery platform, proven track record in nuclear receptors, and our experience in managing collaborations, I strongly believe in our ability to again deliver innovative drug development candidates to our partners”.
Denis Zeyer, CEO of NovAliX, stated, “Ten years ago we built the company on the academic legacy of Pierre Chambon and Dino Moras, world class scientists, who pioneered the field of structural biology and nuclear receptors. We have turned that academic excellence into promising pharmaceutical candidates and this alliance is the opportunity to further extend that success”.
NovAliX is providing enabling chemistry and innovative biophysical technologies to support the pharmaceutical research needs for structure- and fragment based drug discovery. With its proprietary Graffinity SPR technology, X-ray protein crystallography, native mass spectrometry, proprietary NMR methodologies and chemistry expertise, NovAliX offers comprehensive integrated services for small molecule drug discovery. NovAliX Group, a team of 130 scientists, is located in Strasbourg-Illkirch (France) and Heidelberg (NovAliX’s Graffinity subsidiary in Germany).
Inventiva is a first-class drug discovery organization dedicated to providing IND-ready drug development candidates in therapeutic areas of high unmet medical need. Over the past 10 years Inventiva’s team has develop a proprietary expertise in the biology and medicinal chemistry of liganded and orphan nuclear receptors, with a strong track-record in the discovery of clinical candidates. At its research centre based in Dijon (France), Inventiva’s team of 85 scientists with extensive pharmaceutical industry background offers a high quality and efficient one-stop-shop solution for drug discovery collaborations.
Denis Zeyer, CEO
Bld Sébastien Brant, BP 30170
F-67405 Illkirch CEDEX FRANCE
Pierre Broqua, CSO
50 rue de Dijon
21121 Daix FRANCE